Evaluation of a compression resistant matrix for recombinant human bone morphogenetic protein-2

被引:20
作者
Lu, Sheldon X. [1 ,4 ]
Fiorini, Tiago [1 ]
Lee, Jaebum [1 ]
Prasad, Hari S. [2 ]
Buxton, Amanda N. [3 ]
Bisch, Fredrick C. [4 ]
Dixon, Douglas R. [4 ]
Susin, Cristiano [1 ]
Wikesjoe, Ulf M. E. [1 ]
机构
[1] Georgia Regents Univ, LAPCR, Coll Dent Med, Augusta, GA 30912 USA
[2] Univ Minnesota, Hard Tissue Res Lab, Minneapolis, MN USA
[3] Medtron Spinal, Biol, Memphis, TN USA
[4] USA, Adv Educ Program Periodont, Ft Gordon, GA USA
关键词
biomaterials; bone; bone morphogenetic protein; osseointegration; tissue engineering; ALVEOLAR RIDGE AUGMENTATION; IMPLANT DEFECT MODEL; HISTOLOGIC OBSERVATIONS; CLINICAL-IMPLICATIONS; GRINDING TECHNIQUE; NONHUMAN-PRIMATES; TITANIUM IMPLANTS; BULKING AGENT; SPINE FUSION; BETA FAMILY;
D O I
10.1111/jcpe.12109
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background Previous studies document the therapeutic potential of recombinant human bone morphogenetic protein-2 (rhBMP-2) in an absorbable collagen sponge (ACS) carrier for indications in the axial and appendicular skeleton. Nevertheless, the ACS does not comprise structural integrity to adequately support bone formation for onlay indications. The objective of this study was to evaluate local bone formation and osseointegration following surgical implantation of rhBMP-2 soak-loaded onto a compression resistant matrix (CRM). Methods Routine, contralateral, critical-size, supraalveolar, peri-implant defects in five adult male Hound Labrador mongrel dogs received 0.8mg rhBMP-2 soak-loaded onto either the ACS (benchmark control) or a CRM (collagen/-TCP/hydroxyapatite) followed by submerged wound closure for primary intention healing. The animals were euthanized at 8weeks for histologic/histometric evaluation. Results Healing was uneventful albeit considerable initial swelling was observed for either treatment. Sites receiving rhBMP-2/CRM showed significantly increased bone area (20.0 +/- 0.9 versus 12.3 +/- 2.6mm2, p=0.03) and bone density (24.1 +/- 1.4% versus 14.6 +/- 2.0%, p=0.04) compared with those receiving rhBMP-2/ACS. There were no significant differences between treatments for new bone height and osseointegration. Woven and lamellar trabecular bone lined with abundant osteoid was observed for all sites. Inconsistent cortex formation confirmed the immature nature of the newly formed bone. Seroma formation was observed for both treatments (80-100% of the animals/implants). Sites receiving rhBMP-2/CRM showed residual ceramic granules undergoing biodegradation, including accumulation of foamy macrophages. Conclusions rhBMP-2/CRM supports bone formation of clinically relevant geometry. Longer observation intervals as well as dose variations appear necessary to capture maturation of the newly formed bone, elimination of residual ceramic granules and resolution of seroma formation(s).
引用
收藏
页码:688 / 697
页数:10
相关论文
共 50 条
[31]   Human periodontal ligament cell responses to recombinant human bone morphogenetic protein-2 with and without bone allografts [J].
Markopoulou, CE ;
Vrotsos, IA ;
Vavouraki, HN ;
Dereka, XE ;
Mantzavinos, ZS .
JOURNAL OF PERIODONTOLOGY, 2003, 74 (07) :982-989
[32]   Comparison of Bone Regeneration in Different Forms of Bovine Bone Scaffolds with Recombinant Human Bone Morphogenetic Protein-2 [J].
Seok, Hyun ;
Kim, Hee-Youl ;
Kang, Dong-Cheol ;
Park, Jung-Ho ;
Park, Jong Hoon .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (20)
[33]   Osteoinduction by repeat plasmid injection of human bone morphogenetic protein-2 [J].
Osawa, Kenji ;
Okubo, Yasunori ;
Nakao, Kazumasa ;
Koyama, Noriaki ;
Bessho, Kazuhisa .
JOURNAL OF GENE MEDICINE, 2010, 12 (12) :937-944
[34]   Evaluation of Implants Coated With Recombinant Human Bone Morphogenetic Protein-2 and Vacuum-Dried Using the Critical-Size Supraalveolar Pen-Implant Defect Model in Dogs [J].
Decker, John F. ;
Lee, Jaebum ;
Cortella, Carlo Alberto ;
Polimeni, Giuseppe ;
Rohrer, Michael D. ;
Wozney, John M. ;
Hall, Jan ;
Susin, Cristiano ;
Wikesjoe, Ulf M. E. .
JOURNAL OF PERIODONTOLOGY, 2010, 81 (12) :1839-1849
[35]   Changes in Recombinant Human Bone Morphogenetic Protein-2 Use in Posterior Fusion Over the Past Two Decades [J].
Nabizadeh, Naveed ;
Glassman, Steven D. ;
Djurasovic, Mladen ;
Crawford, Charles H. ;
Gum, Jeffrey L. ;
Carreon, Leah .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (09)
[36]   In vitro cellular responses to bioerodible particles loaded with recombinant human bone morphogenetic protein-2 [J].
Puleo, DA ;
Huh, WW ;
Duggirala, SS ;
DeLuca, PP .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, 1998, 41 (01) :104-110
[37]   Outcomes of Alveolar Ridge Preservation With Recombinant Human Bone Morphogenetic Protein-2: A Systematic Review [J].
Moslemi, Neda ;
Khoshkam, Vahid ;
Rafiei, Sahar Chokami ;
Bahrami, Naghmeh ;
Aslroosta, Hoori .
IMPLANT DENTISTRY, 2018, 27 (03) :351-362
[38]   Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2 [J].
Villavicencio, AT ;
Burneikiene, S ;
Nelson, EL ;
Bulsara, KR ;
Favors, M ;
Thramann, J .
JOURNAL OF NEUROSURGERY-SPINE, 2005, 3 (06) :436-443
[39]   Randomized study evaluating recombinant human bone morphogenetic protein-2 for extraction socket augmentation [J].
Fiorellini, JP ;
Howell, TH ;
Cochran, D ;
Malmquist, J ;
Lilly, LC ;
Spagnoli, D ;
Toljanic, J ;
Jones, A ;
Nevins, M .
JOURNAL OF PERIODONTOLOGY, 2005, 76 (04) :605-613
[40]   Effects of recombinant human bone morphogenetic protein-2 on differentiation of cells isolated from human bone, muscle, and skin [J].
Kawasaki, K ;
Aihara, M ;
Honmo, J ;
Sakurai, S ;
Fujimaki, Y ;
Sakamoto, K ;
Fujimaki, E ;
Wozney, JM ;
Yamaguchi, A .
BONE, 1998, 23 (03) :223-231